FindTrial
Sign In

Research on Predicting Immune Checkpoint Inhibitor Response and Immune-Related Adverse Events Based on LAFA

Research on Predicting Immune Checkpoint Inhibitor Response and Immune-Related Adverse Events Based on LAFA

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500100904
Enrollment
Unknown
Registered
2025-04-16
Start date
2025-04-21
Completion date
Unknown
Last updated
2025-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer, cholangiocarcinoma, liver cancer, esophageal cancer

Interventions

Response group:NA
Non-response group:NA

Sponsors

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >= 18 years. 2. Confirmed diagnosis of gastric cancer, cholangiocarcinoma, liver cancer, or esophageal cancer. 3. No prior history of cancer immunotherapy. 4. Willing to participate in the study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Pregnant or breastfeeding women. 2. Individuals who are unable to understand the study content or comply with the treatment protocol. 3. Vulnerable populations other than illiterate individuals, including those with mental illness, cognitive impairment, or critical illness.

Design outcomes

Primary

MeasureTime frame
Treatment response;—

Countries

China

Contacts

Public ContactQian Cao

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

caoq@srrsh.com+86 135 8870 6896

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026